Key Findings
Portal Biotechnologies has successfully raised $9 million to bolster and expand its proprietary cell engineering platform. This platform has garnered significant attention, attracting partnerships with major pharmaceutical entities such as Merck & Co. and AbbVie, underscoring its potential to revolutionize cell therapy manufacturing and delivery. The funding will primarily support the advancement of its innovative mechanoporation technology for efficient intracellular molecule delivery.
Technical / Clinical Details
- Mechanoporation Technology: At the core of Portal Biotechnologies’ platform is mechanoporation, a non-viral physical method that creates temporary, microscopic pores in cell membranes through mechanical force. This allows for direct and efficient delivery of various molecules, including genetic material (mRNA, DNA) and proteins, into cells. Crucially, by avoiding viral vectors, this technology bypasses concerns related to immunogenicity and insertional mutagenesis.
- Enhanced Molecular Delivery: Compared to traditional methods like electroporation or lipid nanoparticle (LNP) delivery, mechanoporation offers the potential for high delivery efficiency and cell viability while minimizing cellular stress and damage. This translates to improved yield and quality of cell therapy products.
- Point-of-Care Manufacturing: With backing from the Defense Advanced Research Projects Agency (DARPA), Portal Biotechnologies is actively developing a portable device for point-of-care (PoC) cell therapy manufacturing. This device aims to enable rapid, on-site production of cell therapies in clinical settings, dramatically reducing logistical complexities and manufacturing lead times that currently plague the field.
Background & Context
The cell and gene therapy sector, while offering transformative treatments, faces significant hurdles, including high manufacturing costs, complex supply chains, and prolonged turnaround times. Autologous cell therapies, which require retrieving a patient’s cells, shipping them to a centralized manufacturing facility for processing, and then returning them to the patient, are particularly time-consuming and expensive, limiting patient access. Non-viral delivery methods and PoC manufacturing approaches, such as those championed by Portal Biotechnologies, are critical for overcoming these challenges and substantially enhancing the commercial viability and widespread adoption of cell therapies.
Strategic Significance & Outlook
This $9 million funding round is a crucial step for Portal Biotechnologies to further develop its technology and advance its clinical applications through collaborations with Merck & Co. and AbbVie. The successful development of a PoC cell therapy manufacturing device, in particular, has the potential to fundamentally transform the cell therapy delivery model. This would allow more patients to receive timely and cost-effective treatments, significantly expanding access. The technology is poised to have a dual impact on the cell therapy market: reducing manufacturing costs and broadening accessibility, thereby fueling the overall growth and maturation of the industry.
Source: https://firstwordhealthtech.com/story/7630258
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments